Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: Phase III study results

BACKGROUND: This study evaluated the efficacy and safety of the long-acting β(2)-agonist formoterol in patients with moderate-to-severe COPD. METHODS: This double-blind, placebo-controlled, parallel-group, multinational phase III study randomized patients ≥ 40 years of age with moderate-to-severe CO...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bogdan, Miron A, Aizawa, Hisamichi, Fukuchi, Yoshinosuke, Mishima, Michiaki, Nishimura, Masaharu, Ichinose, Masakazu
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2011
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3233513/
https://ncbi.nlm.nih.gov/pubmed/22085439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2466-11-51
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia